ISTH 2021 – Blackstone’s Novartis spin-out scores
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
Celldex looks beyond oncology for a resurgence
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
After Immunogen and Sutro, Bristol buys into the folate story
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
A broader use for Regeneron’s Covid-19 antibody combo
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
